Moxidectin is under clinical development by Medicines Development for Global Health and currently in Phase III for Elephantiasis (Lymphatic Filariasis). According to GlobalData, Phase III drugs for Elephantiasis (Lymphatic Filariasis) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Moxidectin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Moxidectin overview
Moxidectin is a semisynthetic derivative of nemadectin and acts as an anthelmintic agent. It is formulated as tablets for oral route of administration. Moxidectin is indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. Moxidectin is under investigation for the treatment of scabies, onchocerciasis in children, soil-transmitted helminths, strongyloides, lymphatic filariasis and head lice.
Medicines Development for Global Health overview
Medicines Development for Global Health (MDGH) is a not-for-profit organization. It primarily focuses on the research, development, and delivery of new and improved medicines. The company’s main focus is on diseases that disproportionately affect low- and middle-income countries. MDGH’s product portfolio includes treatments for a range of neglected diseases such as onchocerciasis, scabies, soil-transmitted helminths, lymphatic filariasis, strongyloidiasis, head lice, leprosy type 2 reactions, and tuberculosis. The company’s pipeline products include moxidectin, dovramilast. MDGH is headquartered in Southbank, Victoria, Australia.
For a complete picture of Moxidectin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
